Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Identifieur interne : 000703 ( Main/Exploration ); précédent : 000702; suivant : 000704Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Auteurs : Milena Gianfrancesco [États-Unis] ; Kimme L. Hyrich [Royaume-Uni] ; Sarah Al-Adely [Royaume-Uni] ; Loreto Carmona [Espagne] ; Maria I. Danila [États-Unis] ; Laure Gossec [France] ; Zara Izadi [États-Unis] ; Lindsay Jacobsohn [États-Unis] ; Patricia Katz [États-Unis] ; Saskia Lawson-Tovey [Royaume-Uni] ; Elsa F. Mateus [Portugal] ; Stephanie Rush [États-Unis] ; Gabriela Schmajuk [États-Unis] ; Julia Simard [États-Unis] ; Anja Strangfeld [Allemagne] ; Laura Trupin [États-Unis] ; Katherine D. Wysham [États-Unis] ; Suleman Bhana [États-Unis] ; Wendy Costello [Irlande (pays)] ; Rebecca Grainger [Nouvelle-Zélande] ; Jonathan S. Hausmann [États-Unis] ; Jean W. Liew [États-Unis] ; Emily Sirotich [Canada] ; Paul Sufka [États-Unis] ; Zachary S. Wallace [États-Unis] ; Jinoos Yazdany [États-Unis] ; Pedro M. Machado [Royaume-Uni] ; Philip C. Robinson [Australie]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2020.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse multifactorielle (MeSH), Anti-inflammatoires non stéroïdiens (usage thérapeutique), Antipaludiques (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Arthrite psoriasique (complications), Arthrite psoriasique (traitement médicamenteux), Betacoronavirus (MeSH), Enregistrements (MeSH), Facteurs de protection (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Glucocorticoïdes (usage thérapeutique), Hospitalisation (statistiques et données numériques), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (complications), Infections à coronavirus (mortalité), Infections à coronavirus (thérapie), Inhibiteurs des Janus kinases (usage thérapeutique), Jeune adulte (MeSH), Lupus érythémateux disséminé (complications), Lupus érythémateux disséminé (traitement médicamenteux), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (mortalité), Pneumopathie virale (thérapie), Polyarthrite rhumatoïde (complications), Polyarthrite rhumatoïde (traitement médicamenteux), Prednisone (usage thérapeutique), Produits biologiques (usage thérapeutique), Rhumatismes (complications), Rhumatismes (traitement médicamenteux), Spondylarthropathies (complications), Spondylarthropathies (traitement médicamenteux), Sujet âgé (MeSH), Vascularite (complications), Vascularite (traitement médicamenteux).
- MESH :
- mortalité : Infections à coronavirus, Pneumopathie virale.
- statistiques et données numériques : Hospitalisation.
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Arthrite psoriasique, Lupus érythémateux disséminé, Polyarthrite rhumatoïde, Rhumatismes, Spondylarthropathies, Vascularite.
- usage thérapeutique : Anti-inflammatoires non stéroïdiens, Antipaludiques, Antirhumatismaux, Arthrite psoriasique, Glucocorticoïdes, Infections à coronavirus, Inhibiteurs des Janus kinases, Lupus érythémateux disséminé, Pneumopathie virale, Polyarthrite rhumatoïde, Prednisone, Produits biologiques, Rhumatismes, Spondylarthropathies, Vascularite.
- Adolescent, Adulte, Adulte d'âge moyen, Analyse multifactorielle, Betacoronavirus, Enregistrements, Facteurs de protection, Facteurs de risque, Femelle, Humains, Indice de gravité de la maladie, Jeune adulte, Mâle, Pandémies, Sujet âgé.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Antimalarials (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Psoriatic (complications), Arthritis, Psoriatic (drug therapy), Arthritis, Rheumatoid (complications), Arthritis, Rheumatoid (drug therapy), Betacoronavirus (MeSH), Biological Products (therapeutic use), COVID-19 (MeSH), Coronavirus Infections (complications), Coronavirus Infections (mortality), Coronavirus Infections (therapy), Female (MeSH), Glucocorticoids (therapeutic use), Hospitalization (statistics & numerical data), Humans (MeSH), Janus Kinase Inhibitors (therapeutic use), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Male (MeSH), Middle Aged (MeSH), Multivariate Analysis (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (mortality), Pneumonia, Viral (therapy), Prednisone (therapeutic use), Protective Factors (MeSH), Registries (MeSH), Rheumatic Diseases (complications), Rheumatic Diseases (drug therapy), Risk Factors (MeSH), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH), Spondylarthropathies (complications), Spondylarthropathies (drug therapy), Tumor Necrosis Factor Inhibitors (therapeutic use), Vasculitis (complications), Vasculitis (drug therapy), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Inflammatory Agents, Non-Steroidal, Antimalarials, Antirheumatic Agents, Biological Products, Glucocorticoids, Janus Kinase Inhibitors, Prednisone, Tumor Necrosis Factor Inhibitors.
- complications : Arthritis, Psoriatic, Arthritis, Rheumatoid, Coronavirus Infections, Lupus Erythematosus, Systemic, Pneumonia, Viral, Rheumatic Diseases, Spondylarthropathies, Vasculitis.
- drug therapy : Arthritis, Psoriatic, Arthritis, Rheumatoid, Lupus Erythematosus, Systemic, Rheumatic Diseases, Spondylarthropathies, Vasculitis.
- mortality : Coronavirus Infections, Pneumonia, Viral.
- statistics & numerical data : Hospitalization.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Adolescent, Adult, Aged, Betacoronavirus, COVID-19, Female, Humans, Male, Middle Aged, Multivariate Analysis, Pandemics, Protective Factors, Registries, Risk Factors, SARS-CoV-2, Severity of Illness Index, Young Adult.
Abstract
OBJECTIVES
COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.
METHODS
Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.
RESULTS
A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.
CONCLUSIONS
We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.
DOI: 10.1136/annrheumdis-2020-217871
PubMed: 32471903
PubMed Central: PMC7299648
Affiliations:
- Allemagne, Australie, Canada, Espagne, France, Irlande (pays), Nouvelle-Zélande, Portugal, Royaume-Uni, États-Unis
- Alabama, Angleterre, Berlin, Californie, Communauté de Madrid, Grand Londres, Grand Manchester, Massachusetts, Minnesota, Ontario, Washington (État), État de New York, Île-de-France
- Berlin, Hamilton (Ontario), Londres, Madrid, Manchester, Paris, Seattle
- University College de Londres, Université McMaster, Université de Manchester, Université de Washington
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.</title><author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hyrich, Kimme L" sort="Hyrich, Kimme L" uniqKey="Hyrich K" first="Kimme L" last="Hyrich">Kimme L. Hyrich</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation></author><author><name sortKey="Al Adely, Sarah" sort="Al Adely, Sarah" uniqKey="Al Adely S" first="Sarah" last="Al-Adely">Sarah Al-Adely</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation></author><author><name sortKey="Carmona, Loreto" sort="Carmona, Loreto" uniqKey="Carmona L" first="Loreto" last="Carmona">Loreto Carmona</name><affiliation wicri:level="3"><nlm:affiliation>Instituto de Salud Musculoesquelética, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Musculoesquelética, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Danila, Maria I" sort="Danila, Maria I" uniqKey="Danila M" first="Maria I" last="Danila">Maria I. Danila</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name><affiliation wicri:level="3"><nlm:affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Izadi, Zara" sort="Izadi, Zara" uniqKey="Izadi Z" first="Zara" last="Izadi">Zara Izadi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jacobsohn, Lindsay" sort="Jacobsohn, Lindsay" uniqKey="Jacobsohn L" first="Lindsay" last="Jacobsohn">Lindsay Jacobsohn</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Katz, Patricia" sort="Katz, Patricia" uniqKey="Katz P" first="Patricia" last="Katz">Patricia Katz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lawson Tovey, Saskia" sort="Lawson Tovey, Saskia" uniqKey="Lawson Tovey S" first="Saskia" last="Lawson-Tovey">Saskia Lawson-Tovey</name><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Mateus, Elsa F" sort="Mateus, Elsa F" uniqKey="Mateus E" first="Elsa F" last="Mateus">Elsa F. Mateus</name><affiliation wicri:level="1"><nlm:affiliation>Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Rush, Stephanie" sort="Rush, Stephanie" uniqKey="Rush S" first="Stephanie" last="Rush">Stephanie Rush</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simard, Julia" sort="Simard, Julia" uniqKey="Simard J" first="Julia" last="Simard">Julia Simard</name><affiliation wicri:level="2"><nlm:affiliation>Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Strangfeld, Anja" sort="Strangfeld, Anja" uniqKey="Strangfeld A" first="Anja" last="Strangfeld">Anja Strangfeld</name><affiliation wicri:level="3"><nlm:affiliation>Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Trupin, Laura" sort="Trupin, Laura" uniqKey="Trupin L" first="Laura" last="Trupin">Laura Trupin</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wysham, Katherine D" sort="Wysham, Katherine D" uniqKey="Wysham K" first="Katherine D" last="Wysham">Katherine D. Wysham</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Bhana, Suleman" sort="Bhana, Suleman" uniqKey="Bhana S" first="Suleman" last="Bhana">Suleman Bhana</name><affiliation wicri:level="2"><nlm:affiliation>Crystal Run Healthcare, Middletown, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crystal Run Healthcare, Middletown, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Costello, Wendy" sort="Costello, Wendy" uniqKey="Costello W" first="Wendy" last="Costello">Wendy Costello</name><affiliation wicri:level="1"><nlm:affiliation>Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Irish Children's Arthritis Network (iCAN), Tipperary</wicri:regionArea><wicri:noRegion>Tipperary</wicri:noRegion></affiliation></author><author><name sortKey="Grainger, Rebecca" sort="Grainger, Rebecca" uniqKey="Grainger R" first="Rebecca" last="Grainger">Rebecca Grainger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Otago, Wellington, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Medicine, University of Otago, Wellington</wicri:regionArea><wicri:noRegion>Wellington</wicri:noRegion></affiliation></author><author><name sortKey="Hausmann, Jonathan S" sort="Hausmann, Jonathan S" uniqKey="Hausmann J" first="Jonathan S" last="Hausmann">Jonathan S. Hausmann</name><affiliation wicri:level="2"><nlm:affiliation>Boston Children's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boston Children's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Liew, Jean W" sort="Liew, Jean W" uniqKey="Liew J" first="Jean W" last="Liew">Jean W. Liew</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Sirotich, Emily" sort="Sirotich, Emily" uniqKey="Sirotich E" first="Emily" last="Sirotich">Emily Sirotich</name><affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Arthritis Patient Alliance, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Sufka, Paul" sort="Sufka, Paul" uniqKey="Sufka P" first="Paul" last="Sufka">Paul Sufka</name><affiliation wicri:level="2"><nlm:affiliation>Healthpartners, St Paul, Minnesota, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Healthpartners, St Paul, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Faculty of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32471903</idno><idno type="pmid">32471903</idno><idno type="doi">10.1136/annrheumdis-2020-217871</idno><idno type="pmc">PMC7299648</idno><idno type="wicri:Area/Main/Corpus">000671</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000671</idno><idno type="wicri:Area/Main/Curation">000671</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000671</idno><idno type="wicri:Area/Main/Exploration">000671</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.</title><author><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Hyrich, Kimme L" sort="Hyrich, Kimme L" uniqKey="Hyrich K" first="Kimme L" last="Hyrich">Kimme L. Hyrich</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation></author><author><name sortKey="Al Adely, Sarah" sort="Al Adely, Sarah" uniqKey="Al Adely S" first="Sarah" last="Al-Adely">Sarah Al-Adely</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation></author><author><name sortKey="Carmona, Loreto" sort="Carmona, Loreto" uniqKey="Carmona L" first="Loreto" last="Carmona">Loreto Carmona</name><affiliation wicri:level="3"><nlm:affiliation>Instituto de Salud Musculoesquelética, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Instituto de Salud Musculoesquelética, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Danila, Maria I" sort="Danila, Maria I" uniqKey="Danila M" first="Maria I" last="Danila">Maria I. Danila</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name><affiliation wicri:level="3"><nlm:affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Izadi, Zara" sort="Izadi, Zara" uniqKey="Izadi Z" first="Zara" last="Izadi">Zara Izadi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Jacobsohn, Lindsay" sort="Jacobsohn, Lindsay" uniqKey="Jacobsohn L" first="Lindsay" last="Jacobsohn">Lindsay Jacobsohn</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Katz, Patricia" sort="Katz, Patricia" uniqKey="Katz P" first="Patricia" last="Katz">Patricia Katz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Lawson Tovey, Saskia" sort="Lawson Tovey, Saskia" uniqKey="Lawson Tovey S" first="Saskia" last="Lawson-Tovey">Saskia Lawson-Tovey</name><affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester</wicri:regionArea><wicri:noRegion>Greater Manchester</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName><orgName type="university">Université de Manchester</orgName></affiliation></author><author><name sortKey="Mateus, Elsa F" sort="Mateus, Elsa F" uniqKey="Mateus E" first="Elsa F" last="Mateus">Elsa F. Mateus</name><affiliation wicri:level="1"><nlm:affiliation>Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Rush, Stephanie" sort="Rush, Stephanie" uniqKey="Rush S" first="Stephanie" last="Rush">Stephanie Rush</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Simard, Julia" sort="Simard, Julia" uniqKey="Simard J" first="Julia" last="Simard">Julia Simard</name><affiliation wicri:level="2"><nlm:affiliation>Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Strangfeld, Anja" sort="Strangfeld, Anja" uniqKey="Strangfeld A" first="Anja" last="Strangfeld">Anja Strangfeld</name><affiliation wicri:level="3"><nlm:affiliation>Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Trupin, Laura" sort="Trupin, Laura" uniqKey="Trupin L" first="Laura" last="Trupin">Laura Trupin</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Wysham, Katherine D" sort="Wysham, Katherine D" uniqKey="Wysham K" first="Katherine D" last="Wysham">Katherine D. Wysham</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Bhana, Suleman" sort="Bhana, Suleman" uniqKey="Bhana S" first="Suleman" last="Bhana">Suleman Bhana</name><affiliation wicri:level="2"><nlm:affiliation>Crystal Run Healthcare, Middletown, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crystal Run Healthcare, Middletown, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Costello, Wendy" sort="Costello, Wendy" uniqKey="Costello W" first="Wendy" last="Costello">Wendy Costello</name><affiliation wicri:level="1"><nlm:affiliation>Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Irish Children's Arthritis Network (iCAN), Tipperary</wicri:regionArea><wicri:noRegion>Tipperary</wicri:noRegion></affiliation></author><author><name sortKey="Grainger, Rebecca" sort="Grainger, Rebecca" uniqKey="Grainger R" first="Rebecca" last="Grainger">Rebecca Grainger</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University of Otago, Wellington, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>Department of Medicine, University of Otago, Wellington</wicri:regionArea><wicri:noRegion>Wellington</wicri:noRegion></affiliation></author><author><name sortKey="Hausmann, Jonathan S" sort="Hausmann, Jonathan S" uniqKey="Hausmann J" first="Jonathan S" last="Hausmann">Jonathan S. Hausmann</name><affiliation wicri:level="2"><nlm:affiliation>Boston Children's Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Boston Children's Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Liew, Jean W" sort="Liew, Jean W" uniqKey="Liew J" first="Jean W" last="Liew">Jean W. Liew</name><affiliation wicri:level="4"><nlm:affiliation>University of Washington, Seattle, Washington, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Sirotich, Emily" sort="Sirotich, Emily" uniqKey="Sirotich E" first="Emily" last="Sirotich">Emily Sirotich</name><affiliation wicri:level="4"><nlm:affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario</wicri:regionArea><orgName type="university">Université McMaster</orgName><placeName><settlement type="city">Hamilton (Ontario)</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Arthritis Patient Alliance, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Sufka, Paul" sort="Sufka, Paul" uniqKey="Sufka P" first="Paul" last="Sufka">Paul Sufka</name><affiliation wicri:level="2"><nlm:affiliation>Healthpartners, St Paul, Minnesota, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Healthpartners, St Paul, Minnesota</wicri:regionArea><placeName><region type="state">Minnesota</region></placeName></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="2"><nlm:affiliation>Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName><orgName type="university">University College de Londres</orgName></affiliation><affiliation wicri:level="3"><nlm:affiliation>University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><nlm:affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.</nlm:affiliation><country wicri:rule="url">Australie</country><wicri:regionArea>Faculty of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Antimalarials (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Psoriatic (complications)</term><term>Arthritis, Psoriatic (drug therapy)</term><term>Arthritis, Rheumatoid (complications)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Betacoronavirus (MeSH)</term><term>Biological Products (therapeutic use)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (mortality)</term><term>Coronavirus Infections (therapy)</term><term>Female (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Janus Kinase Inhibitors (therapeutic use)</term><term>Lupus Erythematosus, Systemic (complications)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Multivariate Analysis (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (mortality)</term><term>Pneumonia, Viral (therapy)</term><term>Prednisone (therapeutic use)</term><term>Protective Factors (MeSH)</term><term>Registries (MeSH)</term><term>Rheumatic Diseases (complications)</term><term>Rheumatic Diseases (drug therapy)</term><term>Risk Factors (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Spondylarthropathies (complications)</term><term>Spondylarthropathies (drug therapy)</term><term>Tumor Necrosis Factor Inhibitors (therapeutic use)</term><term>Vasculitis (complications)</term><term>Vasculitis (drug therapy)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse multifactorielle (MeSH)</term><term>Anti-inflammatoires non stéroïdiens (usage thérapeutique)</term><term>Antipaludiques (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Arthrite psoriasique (complications)</term><term>Arthrite psoriasique (traitement médicamenteux)</term><term>Betacoronavirus (MeSH)</term><term>Enregistrements (MeSH)</term><term>Facteurs de protection (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (mortalité)</term><term>Infections à coronavirus (thérapie)</term><term>Inhibiteurs des Janus kinases (usage thérapeutique)</term><term>Jeune adulte (MeSH)</term><term>Lupus érythémateux disséminé (complications)</term><term>Lupus érythémateux disséminé (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (mortalité)</term><term>Pneumopathie virale (thérapie)</term><term>Polyarthrite rhumatoïde (complications)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Prednisone (usage thérapeutique)</term><term>Produits biologiques (usage thérapeutique)</term><term>Rhumatismes (complications)</term><term>Rhumatismes (traitement médicamenteux)</term><term>Spondylarthropathies (complications)</term><term>Spondylarthropathies (traitement médicamenteux)</term><term>Sujet âgé (MeSH)</term><term>Vascularite (complications)</term><term>Vascularite (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Antimalarials</term><term>Antirheumatic Agents</term><term>Biological Products</term><term>Glucocorticoids</term><term>Janus Kinase Inhibitors</term><term>Prednisone</term><term>Tumor Necrosis Factor Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Psoriatic</term><term>Arthritis, Rheumatoid</term><term>Coronavirus Infections</term><term>Lupus Erythematosus, Systemic</term><term>Pneumonia, Viral</term><term>Rheumatic Diseases</term><term>Spondylarthropathies</term><term>Vasculitis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Psoriatic</term><term>Arthritis, Rheumatoid</term><term>Lupus Erythematosus, Systemic</term><term>Rheumatic Diseases</term><term>Spondylarthropathies</term><term>Vasculitis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Arthrite psoriasique</term><term>Lupus érythémateux disséminé</term><term>Polyarthrite rhumatoïde</term><term>Rhumatismes</term><term>Spondylarthropathies</term><term>Vascularite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires non stéroïdiens</term><term>Antipaludiques</term><term>Antirhumatismaux</term><term>Arthrite psoriasique</term><term>Glucocorticoïdes</term><term>Infections à coronavirus</term><term>Inhibiteurs des Janus kinases</term><term>Lupus érythémateux disséminé</term><term>Pneumopathie virale</term><term>Polyarthrite rhumatoïde</term><term>Prednisone</term><term>Produits biologiques</term><term>Rhumatismes</term><term>Spondylarthropathies</term><term>Vascularite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Betacoronavirus</term><term>COVID-19</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Pandemics</term><term>Protective Factors</term><term>Registries</term><term>Risk Factors</term><term>SARS-CoV-2</term><term>Severity of Illness Index</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse multifactorielle</term><term>Betacoronavirus</term><term>Enregistrements</term><term>Facteurs de protection</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Jeune adulte</term><term>Mâle</term><term>Pandémies</term><term>Sujet âgé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32471903</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.</ArticleTitle><Pagination><MedlinePgn>859-866</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2020-217871</ELocationID><Abstract><AbstractText Label="OBJECTIVES">COVID-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 hospitalisation status in people with rheumatic disease.</AbstractText><AbstractText Label="METHODS">Case series of individuals with rheumatic disease and COVID-19 from the COVID-19 Global Rheumatology Alliance registry: 24 March 2020 to 20 April 2020. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed.</AbstractText><AbstractText Label="RESULTS">A total of 600 cases from 40 countries were included. Nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. In multivariable-adjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% CI 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMARD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% CI 0.70 to 2.17 and OR 0.74, 95% CI 0.37 to 1.46, respectively). Non-steroidal anti-inflammatory drug (NSAID) use was not associated with hospitalisation status (OR 0.64, 95% CI 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TNF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% CI 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% CI 0.57 to 1.57) was observed.</AbstractText><AbstractText Label="CONCLUSIONS">We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TNF with a decreased odds of hospitalisation in patients with rheumatic disease. Neither exposure to DMARDs nor NSAIDs were associated with increased odds of hospitalisation.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gianfrancesco</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hyrich</LastName><ForeName>Kimme L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Adely</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto de Salud Musculoesquelética, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Danila</LastName><ForeName>Maria I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology and Rheumatology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gossec</LastName><ForeName>Laure</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4528-310X</Identifier><AffiliationInfo><Affiliation>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izadi</LastName><ForeName>Zara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsohn</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katz</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawson-Tovey</LastName><ForeName>Saskia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, Greater Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateus</LastName><ForeName>Elsa F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmajuk</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simard</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Health Research & Policy, Division of Epidemiology and Department of Medicine, Division of Immunology & Rheumatology, Stanford School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strangfeld</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Forschungsbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trupin</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wysham</LastName><ForeName>Katherine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhana</LastName><ForeName>Suleman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Crystal Run Healthcare, Middletown, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costello</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Irish Children's Arthritis Network (iCAN), Tipperary, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grainger</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Otago, Wellington, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hausmann</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Jean W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirotich</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sufka</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Healthpartners, St Paul, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yazdany</LastName><ForeName>Jinoos</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Machado</LastName><ForeName>Pedro M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0002-8411-7972</Identifier><AffiliationInfo><Affiliation>Centre for Rheumatology & Department of Neuromuscular Diseases, University College London (UCL), London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University College London Hospitals (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre (BRC), London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Robinson</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-3156-3418</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia philip.robinson@uq.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metro North Hospital & Health Service, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Global Rheumatology Alliance</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AR075085</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AR074534</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR070155</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Rheumatol. 2020 Aug;16(8):407</RefSource><PMID Version="1">32620941</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015535" MajorTopicYN="N">Arthritis, Psoriatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065840" MajorTopicYN="N">Protective Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="N">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025242" MajorTopicYN="N">Spondylarthropathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="N">Vasculitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">arthritis, rheumatoid</Keyword><Keyword MajorTopicYN="Y">hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="Y">methotrexate</Keyword><Keyword MajorTopicYN="Y">tumor necrosis factor inhibitors</Keyword></KeywordList><CoiStatement>Competing interests: MG reports grants from National Institutes of Health, NIAMS, outside the submitted work. KLH reports she has received speaker’s fees from AbbVie and grant income from BMS, UCB and Pfizer, all unrelated to this manuscript. KLH is also supported by the NIHR Manchester Biomedical Research Centre. SA-A has nothing to disclose. LC has not received fees or personal grants from any laboratory, but her institute works by contract for laboratories among other institutions, such as AbbVie Spain, Eisai, Gebro Pharma, Merck Sharp & Dohme España, S.A., Novartis Farmaceutica, Pfizer, Roche Farma, Sanofi Aventis, Astellas Pharma, Actelion Pharmaceuticals España, Grünenthal GmbH and UCB Pharma. MD reports no competing interests related to this work. She is supported by grants from the National Institute of Health, Pfizer Independent Grants for Learning and Change, Genentech, Horizon Pharma. She has performed consultant work for Amgen, Novartis, Regeneron/Sanofi unrelated to this work. LG reports personal consultant fees from AbbVie, Biogen, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB and grants from Eli Lilly, Mylan, Pfizer, all unrelated to this manuscript. EM reports that LPCDR received support for specific activities: grants from AbbVie, Novartis, Janssen-Cilag, Eli Lilly Portugal, Sanofi, Grünenthal S.A., MSD, Celgene, Medac, Pharmakern, GAfPA; grants and non-financial support from Pfizer; non-financial support from Grünenthal GmbH, outside the submitted work. GS reports no competing interests related to this work. Her work is supported by grants from the National Institutes of Health and Agency for Healthcare Research and Quality. She leads the Data Analytic Center for the American College of Rheumatology, which is unrelated to this work. AS reports grants from a consortium of 13 companies (among them AbbVie, BMS, Celltrion, Fresenius Kabi, Eli Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis and UCB) supporting the German RABBIT register and personal fees from lectures for AbbVie, MSD, Roche, BMS, Pfizer, outside the submitted work. SB reports no competing interests related to this work. He reports non-branded marketing campaigns for Novartis (</CoiStatement> </MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32471903</ArticleId><ArticleId IdType="pii">annrheumdis-2020-217871</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Rheum Dis. 2020 Jun;79(6):734-736</Citation><ArticleIdList><ArticleId IdType="pubmed">32295786</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 Apr 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32321723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2011 Nov;70(11):1914-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21791449</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 Jul;79(7):851-858</Citation><ArticleIdList><ArticleId IdType="pubmed">32503854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 May 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32381561</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Mar 23;368:m1168</Citation><ArticleIdList><ArticleId IdType="pubmed">32205306</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Mar 26;368:m1091</Citation><ArticleIdList><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 Jun;79(6):837-839</Citation><ArticleIdList><ArticleId IdType="pubmed">32332072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2020 Jun 1;59(6):1204-1206</Citation><ArticleIdList><ArticleId IdType="pubmed">32374851</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 19;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Rheumatol. 2020 Apr 16;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32309814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2020 Apr 29;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32349183</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2020 Apr 25;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32335513</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):814-818</Citation><ArticleIdList><ArticleId IdType="pubmed">32253759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 2;395(10234):1407-1409</Citation><ArticleIdList><ArticleId IdType="pubmed">32278362</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Rheumatol. 2020 Jun;16(6):293-294</Citation><ArticleIdList><ArticleId IdType="pubmed">32242121</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 6;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2013 Jan;52(1):53-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23192911</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2372-2374</Citation><ArticleIdList><ArticleId IdType="pubmed">32302078</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive Care Med. 2020 May;46(5):846-848</Citation><ArticleIdList><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2020 Jun 16;172(12):819-821</Citation><ArticleIdList><ArticleId IdType="pubmed">32227189</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Rheum Dis. 2020 May;79(5):667-668</Citation><ArticleIdList><ArticleId IdType="pubmed">32241793</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>Espagne</li><li>France</li><li>Irlande (pays)</li><li>Nouvelle-Zélande</li><li>Portugal</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Alabama</li><li>Angleterre</li><li>Berlin</li><li>Californie</li><li>Communauté de Madrid</li><li>Grand Londres</li><li>Grand Manchester</li><li>Massachusetts</li><li>Minnesota</li><li>Ontario</li><li>Washington (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Berlin</li><li>Hamilton (Ontario)</li><li>Londres</li><li>Madrid</li><li>Manchester</li><li>Paris</li><li>Seattle</li></settlement><orgName><li>University College de Londres</li><li>Université McMaster</li><li>Université de Manchester</li><li>Université de Washington</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Gianfrancesco, Milena" sort="Gianfrancesco, Milena" uniqKey="Gianfrancesco M" first="Milena" last="Gianfrancesco">Milena Gianfrancesco</name></region><name sortKey="Bhana, Suleman" sort="Bhana, Suleman" uniqKey="Bhana S" first="Suleman" last="Bhana">Suleman Bhana</name><name sortKey="Danila, Maria I" sort="Danila, Maria I" uniqKey="Danila M" first="Maria I" last="Danila">Maria I. Danila</name><name sortKey="Hausmann, Jonathan S" sort="Hausmann, Jonathan S" uniqKey="Hausmann J" first="Jonathan S" last="Hausmann">Jonathan S. Hausmann</name><name sortKey="Hausmann, Jonathan S" sort="Hausmann, Jonathan S" uniqKey="Hausmann J" first="Jonathan S" last="Hausmann">Jonathan S. Hausmann</name><name sortKey="Izadi, Zara" sort="Izadi, Zara" uniqKey="Izadi Z" first="Zara" last="Izadi">Zara Izadi</name><name sortKey="Jacobsohn, Lindsay" sort="Jacobsohn, Lindsay" uniqKey="Jacobsohn L" first="Lindsay" last="Jacobsohn">Lindsay Jacobsohn</name><name sortKey="Katz, Patricia" sort="Katz, Patricia" uniqKey="Katz P" first="Patricia" last="Katz">Patricia Katz</name><name sortKey="Liew, Jean W" sort="Liew, Jean W" uniqKey="Liew J" first="Jean W" last="Liew">Jean W. Liew</name><name sortKey="Rush, Stephanie" sort="Rush, Stephanie" uniqKey="Rush S" first="Stephanie" last="Rush">Stephanie Rush</name><name sortKey="Schmajuk, Gabriela" sort="Schmajuk, Gabriela" uniqKey="Schmajuk G" first="Gabriela" last="Schmajuk">Gabriela Schmajuk</name><name sortKey="Simard, Julia" sort="Simard, Julia" uniqKey="Simard J" first="Julia" last="Simard">Julia Simard</name><name sortKey="Sufka, Paul" sort="Sufka, Paul" uniqKey="Sufka P" first="Paul" last="Sufka">Paul Sufka</name><name sortKey="Trupin, Laura" sort="Trupin, Laura" uniqKey="Trupin L" first="Laura" last="Trupin">Laura Trupin</name><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><name sortKey="Wysham, Katherine D" sort="Wysham, Katherine D" uniqKey="Wysham K" first="Katherine D" last="Wysham">Katherine D. Wysham</name><name sortKey="Yazdany, Jinoos" sort="Yazdany, Jinoos" uniqKey="Yazdany J" first="Jinoos" last="Yazdany">Jinoos Yazdany</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Hyrich, Kimme L" sort="Hyrich, Kimme L" uniqKey="Hyrich K" first="Kimme L" last="Hyrich">Kimme L. Hyrich</name></region><name sortKey="Al Adely, Sarah" sort="Al Adely, Sarah" uniqKey="Al Adely S" first="Sarah" last="Al-Adely">Sarah Al-Adely</name><name sortKey="Al Adely, Sarah" sort="Al Adely, Sarah" uniqKey="Al Adely S" first="Sarah" last="Al-Adely">Sarah Al-Adely</name><name sortKey="Hyrich, Kimme L" sort="Hyrich, Kimme L" uniqKey="Hyrich K" first="Kimme L" last="Hyrich">Kimme L. Hyrich</name><name sortKey="Lawson Tovey, Saskia" sort="Lawson Tovey, Saskia" uniqKey="Lawson Tovey S" first="Saskia" last="Lawson-Tovey">Saskia Lawson-Tovey</name><name sortKey="Lawson Tovey, Saskia" sort="Lawson Tovey, Saskia" uniqKey="Lawson Tovey S" first="Saskia" last="Lawson-Tovey">Saskia Lawson-Tovey</name><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name><name sortKey="Machado, Pedro M" sort="Machado, Pedro M" uniqKey="Machado P" first="Pedro M" last="Machado">Pedro M. Machado</name></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Carmona, Loreto" sort="Carmona, Loreto" uniqKey="Carmona L" first="Loreto" last="Carmona">Loreto Carmona</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name></region><name sortKey="Gossec, Laure" sort="Gossec, Laure" uniqKey="Gossec L" first="Laure" last="Gossec">Laure Gossec</name></country><country name="Portugal"><noRegion><name sortKey="Mateus, Elsa F" sort="Mateus, Elsa F" uniqKey="Mateus E" first="Elsa F" last="Mateus">Elsa F. Mateus</name></noRegion></country><country name="Allemagne"><region name="Berlin"><name sortKey="Strangfeld, Anja" sort="Strangfeld, Anja" uniqKey="Strangfeld A" first="Anja" last="Strangfeld">Anja Strangfeld</name></region></country><country name="Irlande (pays)"><noRegion><name sortKey="Costello, Wendy" sort="Costello, Wendy" uniqKey="Costello W" first="Wendy" last="Costello">Wendy Costello</name></noRegion></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Grainger, Rebecca" sort="Grainger, Rebecca" uniqKey="Grainger R" first="Rebecca" last="Grainger">Rebecca Grainger</name></noRegion></country><country name="Canada"><region name="Ontario"><name sortKey="Sirotich, Emily" sort="Sirotich, Emily" uniqKey="Sirotich E" first="Emily" last="Sirotich">Emily Sirotich</name></region><name sortKey="Sirotich, Emily" sort="Sirotich, Emily" uniqKey="Sirotich E" first="Emily" last="Sirotich">Emily Sirotich</name></country><country name="Australie"><noRegion><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name></noRegion><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000703 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000703 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32471903
|texte= Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32471903" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |